MASCC Guidelines


> Search by Study Group

Antiemetics
Bone and Musculoskeletal
Cancer Pain (Palliative Care Subgroup)
Education
Fatigue
Geriatrics
Hemostasis
Immuno-Oncology (Neutropenia Subgroup)
Mucositis
Neurological Complications
Neutropenia, Infection & Myelosuppression
Nutrition and Cachexia
Oncodermatology
Oral Care
Palliative Care
Pediatrics
Psychosocial
Survivorship

 

Antiemetics Study Group

DOWNLOAD GUIDELINES - click here   • MASCC resources are available for download by providing a valid email address.

MASCC MEMBERS -  CLICK HERE


NON-MEMBER ACCESS: (*indicates required fields )

Subscribe

* indicates required
Guideline Summary Slide Set (2016 with updates 2019)
Guideline Summary PDF Slide Set (2016 with updates 2019)
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Radiotherapy-Induced Nausea and Vomiting
Ruhlmann CH, Jahn F, Jordan K, Dennis K, Maranzano E, Molassiotis A, Roila FB, Feyer P. Support Care Cancer 2016 Sep 13
2016 Updated MASCC/ESMO Consensus Recommendations: Controlling Nausea and Vomiting with Chemotherapy of Low or Minimal Emetic Potential
Olver I, Ruhlmann CH, Jahn F, Schwartzberg L, Rapoport B, Rittenberg CN, Clark-Snow R. Support Care Cancer. 2016 Aug 30
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Children
Dupuis LL, Sung L, Molassiotis A, Orsey AD, Tissing W, van de Wetering M. Support Care Cancer. 2016 Aug 26
Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following Moderately Emetogenic Chemotherapy
Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B. Support Care Cancer. 2016 Aug 11
Updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy
Dupuis LL, Roscoe JA, Olver I, Aapro M, Molassiotis A. Support Care Cancer. 2016 Aug 10
2016 Updated MASCC/ESMO Consensus Recommendations: Emetic Risk Classification and Evaluation of the Emetogenicity of Antineoplastic Agents
Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, Hesketh PJ. Support Care Cancer. 2016 Aug 8
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy
Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS. Support Care Cancer. 2016 Jul 22
Erratum to: 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following Moderately Emetogenic Chemotherapy
Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B.Support Care Cancer. 2016 Sep 14  No abstract available.

This set of evidence-based guidelines represents several important changes and first-time inclusions.This is the first time that recommendations about management of nausea and vomiting in advanced cancer have been included — as opposed to only nausea and vomiting induced by chemotherapy or radiotherapy — and in this respect, the new MASCC/ESMO guidelines differ from those of NCCN and ASCO. The new guidelines contain recommendations for two new NK1 receptor antagonists, rolapitant and netupitant, the latter given in combination with palonosetron (NEPA), and also discuss the use of olanzapine. The combination of an anthracycline with cyclophosphamide, previously considered of medium emetogenic risk (30-90% risk of vomiting) is now considered a high-risk combination (>90% risk of vomiting). However, this remains a special case, since recommendations for the delayed phase differ from those of other chemotherapies of highly emetogenic risk. In addition, carboplatin is now considered a special case with an indication for triple preventative therapy in the acute phase.

Bone and Musculoskeletal Study Group

DOWNLOAD GUIDELINES - click here   • MASCC resources are available for download by providing a valid email address.

MASCC MEMBERS -  CLICK HERE


NON-MEMBER ACCESS: (*indicates required fields )

Subscribe

* indicates required
Guideline Summary Slide Set (2019)
Guideline Summary (2019)
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline 
Yarom N et al, J Clin Oncol 2019 Jul 22:JCO1901186

Immuno-Oncology (Neutropenia Subgroup)

MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors
Rapoport B, et al. Support Care Cancer 2020 Sept 4:28, pages 6107-6110
Cancer immunotherapy–related adverse events: causes and challenges
Blidner AG, et al. Support Care Cancer 2020 Aug 28:28, pages 6111–6117
MASCC 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities
Cooksley T, et al. Support Care Cancer 2020 Aug 27:28, pages 6175–6181
MASCC 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors
Suarez-Almazor ME, et al. Support Care Cancer 2020 Aug 27:28, pages 6159–6173
MASCC 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity
Shannon VR, et al. Support Care Cancer 2020 Sep 3:28, pages 6145–6157
MASCC 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Choi J, et al. Support Care Cancer 2020 Aug 27:28, pages 6119–6128
MASCC 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors
Dougan M, et al. Support Care Cancer 2020 Aug 27:28, pages 6129–6143

Mucositis Study Group

DOWNLOAD GUIDELINES - click here   • MASCC resources are available for download by providing a valid email address.

MASCC MEMBERS -  CLICK HERE


NON-MEMBER ACCESS: (*indicates required fields )

Subscribe

* indicates required
Guideline Summary Slide Set  (2019/2020 update)
Guideline Summary PDF  (2019/2020 update)
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Elad S, et al. Cancer. 2020 Jul 28. doi: 10.1002/cncr.33100
The MASCC/ISOO Mucositis Guidelines 2019 Update: introduction to the first set of article.
Elad S. Support Care Cancer. 2019 Oct;27(10):3929-3931
The MASCC/ISOO Mucositis Guidelines 2019: the second set of articles and future directions.
Elad S. Support Care Cancer. 2020 May;28(5):2445-2447
Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines.
Logan RM, et al. Support Care Cancer. 2020 May;28(5):2485-2498
Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents.
Yarom N, et al. Support Care Cancer. 2020 May;28(5):2457-2472
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines.
Saunders DP, et al. Support Care Cancer. 2020 May;28(5):2473-2484
Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines.
Correa MEP, et al. Support Care Cancer. 2020 May;28(5):2449-2456
The pathogenesis of mucositis: updated perspectives and emerging targets.
Bowen J, et al.  Support Care Cancer. 2019 Oct;27(10):4023-4033. doi: 10.1007/s00520-019-04893-z
Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.
Bowen JM, et al. Support Care Cancer. 2019 Oct;27(10):4011-4022
Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines.
Hong CHL, et al. Support Care Cancer. 2019 Oct;27(10):3949-3967
Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines.
Ariyawardana A, et al. Support Care Cancer. 2019 Oct;27(10):3985-3995
Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements.
Yarom N, et al. Support Care Cancer. 2019 Oct;27(10):3997-4010
Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines.
Zadik Y, et al. Support Care Cancer. 2019 Oct;27(10):3969-3983
Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods.
Ranna V, et al. Support Care Cancer. 2019 Oct;27(10):3933-3948
Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action.
Wardill HR, et al. Support Care Cancer. 2020 Nov;28(11):5059-5073. doi: 10.1007/s00520-020-05579-7
MASCC/ISOO clinical practice guidelines for the management of mucositis: Sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients
Miranda-Silva W, Gomes-Silva W, et al. Supportive Care in Cancer. 2020

Oncodermatology

DOWNLOAD GUIDELINES - click here   • MASCC resources are available for download by providing a valid email address.

MASCC MEMBERS -  CLICK HERE


NON-MEMBER ACCESS: (*indicates required fields )

Subscribe

* indicates required
Guideline Summary Slide Set (2012)
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
Lacouture ME et al. Support Care Cancer 2011;19(8):1079-1095
Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group
Wong RK et al. Support Care Cancer 2013 Oct;21(10):2933-48

Oral Care Study Group

DOWNLOAD GUIDELINES - click here   • MASCC resources are available for download by providing a valid email address.

MASCC MEMBERS -  CLICK HERE


NON-MEMBER ACCESS: (*indicates required fields )

Subscribe

* indicates required
Guideline Summary Slide Set (2021)
Guideline Summary (2021)
Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline
Mercadante V, et al. J Clin Onco 2021 Sep;39(25):2825-2843 

Palliative Care Study Group

DOWNLOAD GUIDELINES - click here   • MASCC resources are available for download by providing a valid email address.

MASCC MEMBERS -  CLICK HERE


NON-MEMBER ACCESS: (*indicates required fields )

Subscribe

* indicates required
Guideline Summary Slide Set (2016)
Guideline Summary (2016)
Updated MASCC/ESMO Consensus Recommendations: Management of Nausea and Vomiting in Advanced Cancer
Walsh D, et al, Supportive Care in Cancer 2016 Aug 17:25, pages 333–340

 

Last Updated on Tuesday, August 31, 2021 07:43 AM